title: Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease.
abstract: Ebolaviruses are highly infectious pathogens that cause lethal Ebola virus disease (EVD) in humans and non-human primates (NHPs). Due to their high pathogenicity and transmissibility, as well as the potential to be misused as a bioterrorism agent, ebolaviruses would threaten the health of global populations if not controlled. In this review, we describe the origin and structure of ebolaviruses and the development of vaccines from the beginning of the 1980s, including conventional ebolavirus vaccines, DNA vaccines, Ebola virus-like particles (VLPs), vaccinia virus-based vaccines, Venezuelan equine encephalitis virus (VEEV)-like replicon particles, Kunjin virus-based vaccine, recombinant Zaire Ebolavirusx2206;VP30, recombinant cytomegalovirus (CMV)-based vaccines, recombinant rabies virus (RABV)-based vaccines, recombinant paramyxovirus-based vaccines, adenovirus-based vaccines and vesicular stomatitis virus (VSV)-based vaccines. No licensed vaccine or specific treatment is currently available to counteract ebolavirus infection, although DNA plasmids and several viral vector approaches have been evaluated as promising vaccine platforms. These vaccine candidates have been confirmed to be successful in protecting NHPs against lethal infection. Moreover, these vaccine candidates were successfully advanced to clinical trials. The present review provides an update of the current research on Ebola vaccines, with the aim of providing an overview on current prospects in the fight against EVD.
authors.forename: Xiao-Xin
authors.initials: XX
authors.lastname: Wu
authors.forename: Hang-Ping
authors.initials: HP
authors.lastname: Yao
authors.forename: Nan-Ping
authors.initials: NP
authors.lastname: Wu
authors.forename: Hai-Nv
authors.initials: HN
authors.lastname: Gao
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Wu
authors.forename: Chang-Zhong
authors.initials: CZ
authors.lastname: Jin
authors.forename: Xiang-Yun
authors.initials: XY
authors.lastname: Lu
authors.forename: Tian-Shen
authors.initials: TS
authors.lastname: Xie
authors.forename: Lan-Juan
authors.initials: LJ
authors.lastname: Li
mesh_terms: D046129:Ebola Vaccines / Q000276:immunology*; D029043:Ebolavirus / Q000235:genetics* / Q000378:metabolism; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism; D019142:Hemorrhagic Fever, Ebola / Q000473:pathology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology / Q000302:isolation & purification; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D058425:Vaccines, Virus-Like Particle / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism
chemical_list: D046129:Ebola Vaccines; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D058425:Vaccines, Virus-Like Particle; D014764:Viral Proteins